Evolutionary survey of druggable protein targets with respect to their subcellular localizations.

The druggable subset of the human genome, termed the "druggable genome," provides the pharmaceutical industry with a unique opportunity for the advancement of new therapeutic interventions for a multitude of diseases and disorders. To date, there is no systematic assessment of the evolutionary history and nature of the defined druggable proteins derived from the contemporary druggable genome (i.e., proteins that bind or are predicted to bind with high affinity to a biologic). An understanding of drug-protein target interactions in specific cellular compartments is crucial for the optimal therapeutic delivery of pharmaceutical agents, as well as for preclinical drug trials in model animals. This study applied the concept of pharmacophylogenomics, the study of genes, evolution, and drug targets, to conduct an evolutionary survey of drug targets with respect to their subcellular localizations. Using multiple models and modes of druggable genome comparison, the results concordantly indicated that orthologous drug targets with a nuclear localization in the human, macaque, mouse, and rat showed a higher trend for evolutionary conservation compared with drug targets in the cell membrane and the extracellular compartment. As such, this study provides important information regarding druggable protein targets and the druggable genome at the pharmacophylogenomics level.